Eli Lilly and Company vs Huawei Technologies Co., Ltd.: Strategic Comparison

This in-depth comparison examines Eli Lilly and Company and Huawei Technologies Co., Ltd. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Eli Lilly and Company on its own, evaluating Huawei Technologies Co., Ltd., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Eli Lilly and Company and Huawei Technologies Co., Ltd. is widest.

On the headline numbers, Eli Lilly and Company reports annual revenue of $65.2B against $118.5B for Huawei Technologies Co., Ltd., while their respective market capitalizations stand at $700.0B and $120.0B. Eli Lilly and Company is headquartered in United States and Huawei Technologies Co., Ltd. operates from China, and those different home markets shape how each company competes.

Eli Lilly and Company: Revenue at Eli Lilly went from $28.5 billion in 2022 to $45 billion in 2024. That $16.5 billion increase in two years is not a corporate turnaround story — it's the commercial harvest of a single molecule: tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity. The drug became the fastest pharmaceutical product ever to reach $5 billion in annual sales, transforming a 148-year-old Midwestern company into one of America's most valuable corporations at a $700 billion market capitalization. The scientific lineage matters. Lilly produced the world's first commercially available insulin in 1923, giving type 1 diabetic patients who had previously faced certain death a reason to survive. That 1923 achievement planted the company in incretin biology — the study of gut hormones that regulate insulin secretion and appetite — where it would spend decades building intellectual and clinical depth. Tirzepatide is not a lucky discovery. It is the commercial output of that sustained investment. The SURMOUNT-5 trial made a specific claim that reshaped the competitive landscape: tirzepatide produced approximately 47% greater relative weight loss than semaglutide (Wegovy) in a direct head-to-head comparison. That's not a nuanced statistical edge — it's a clinically meaningful difference that gives physicians a reason to prescribe Zepbound over Novo Nordisk's product. The supply shortage that followed was the kind of problem that only hits companies whose demand has genuinely exceeded expectations. Retatrutide, Lilly's triple receptor agonist in Phase 3 development, showed average body weight reduction of approximately 24.2% over 48 weeks in a Phase 2 trial. If that number holds in Phase 3, it would represent the most effective pharmacological weight loss data ever published.

Huawei Technologies Co., Ltd.: Ren Zhengfei retains a nominal 0.7% equity stake in Huawei. The remaining 99.3% is owned by employees through a trade union committee representing over 140,000 participants. That ownership structure — unusual among companies of this scale anywhere in the world — explains some of the decision-making speed and long-term capital allocation tolerance that characterizes Huawei's response to the U.S. Technology embargo. No public shareholders demanding quarterly results. No private equity timeline. The founder holds effective control through veto rights, not equity concentration. The 2019 U.S. Entity List placement was the defining external event of the modern Huawei story. It severed the company from Google's Android services, from TSMC's advanced chip fabrication, from U.S.-origin equipment across its supply chain. The conventional analysis at the time was that Huawei's consumer electronics business would collapse within years. Instead, the company mass-produced 7-nanometer processors using deprecated DUV lithography equipment in the Kirin 9000s and Kirin 9010 chipsets, restoring its premium smartphone competitiveness domestically. The $118.5 billion in FY2024 revenue — up from $94.2 billion in 2022 — was generated while operating under comprehensive U.S. Sanctions. The growth came from sectors where Western alternatives are either unavailable or prohibited: 5G network infrastructure for markets outside the Five Eyes alliance, Digital Power solutions (smart photovoltaic inverters and data center liquid cooling), and domestic Chinese smartphone sales where Huawei commands significant loyalty. 23.4% of revenue — $27.7 billion — went to research and development in FY2024. The R&D workforce of over 114,000 engineers represents 55% of the total 207,000 employees. Those numbers don't describe a company managing decline. They describe a company restructuring its technological supply chain from first principles.

Eli Lilly and Company and Huawei Technologies Co., Ltd. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Eli Lilly and Company and Huawei Technologies Co., Ltd..

Eli Lilly and Company business model: Lilly endured a lost decade marked by clinical failures in Alzheimer's disease research, insulin pricing controversies that drew congressional scrutiny, and generic competition that eroded blockbuster revenues. At its most fundamental level, Lilly's revenue model is straightforward: the company invests heavily in discovering and developing novel drugs, secures patent protection and regulatory approval for those drugs, manufactures them at scale, and sells them at premium prices to patients, healthcare systems, and payers. Insulin pricing has been a politically sensitive issue for Lilly, and in 2023 the company proactively announced it would cap monthly out-of-pocket costs for all insulin products at $35, a decision that absorbed short-term revenue impact but significantly reduced reputational and legislative risk. From a revenue geography perspective, the United States consistently represents the largest single market, accounting for approximately 65 percent of total revenues in 2024, reflecting both the premium pricing environment in American healthcare and the company's deep commercial infrastructure across hospitals, specialty pharmacies, and managed care organizations. The company's pricing and reimbursement strategy reflects the complex political economy of American pharmaceutical markets. Lilly's gross-to-net discount structure — the gap between list prices and the actual net prices after rebates, chargebacks, and discounts to payers and pharmacy benefit managers — has grown substantially as managed care organizations have exerted pricing pressure. Pricing and access policy represents a politically charged challenge with direct financial consequences. The Inflation Reduction Act of 2022 enable the Centers for Medicare and Medicaid Services to negotiate prices directly for high-expenditure drugs, and multiple Lilly products may become subject to negotiated pricing as the program expands in scope. The broader debate over pharmaceutical pricing, including congressional investigations and state-level legislative efforts, creates an ongoing environment of policy uncertainty that affects revenue planning and investor sentiment. Additionally, dozens of biotechnology companies and larger pharmaceutical corporations are developing oral GLP-1 agonists, next-generation dual and triple agonist molecules, and combination weight loss therapies that could fragment the market and compress Lilly's pricing power over the medium term.

Huawei Technologies Co., Ltd. business model: This segment operates on a B2C model, relying on high-volume hardware sales combined with high-margin internet services and app store commissions. The launch of the Mate 60 series and the Pura 70 series, powered by the domestically manufactured Kirin 9000s and Kirin 9010 chipsets, restored Huawei's pricing power in the premium smartphone segment, allowing it to capture significant market share from Apple in the $800+ price tier in China. The financial mechanics of Huawei's model are exceptionally efficient in its core markets, where its brand equity and technological superiority allow it to command premium pricing, but the model faces severe margin compression in international markets where geopolitical restrictions limit its addressable market and force it to offer aggressive discounts to maintain carrier relationships. Huawei differentiates itself by integrating AI and cloud management into its digital power products, offering highly efficient, smart inverters that improved energy yield and liquid-cooling solutions that reduce data center power consumption, allowing it to command premium pricing and capture significant market share in the rapidly growing renewable energy and AI infrastructure sectors. Here's why: the financial mechanics of Huawei's business model are exceptionally efficient in its core markets, where its brand equity and technological superiority allow it to command premium pricing, but the model faces severe margin compression in international markets where geopolitical restrictions limit its addressable market and force it to offer aggressive discounts to maintain carrier relationships. This geographic restriction not only limits Huawei's total addressable market for carrier equipment but also reduces the economies of scale that historically allowed it to undercut Ericsson and Nokia on pricing, forcing the company to compete on software features and network improvement rather than sheer volume. The third major challenge is the intense domestic competition in the cloud computing and enterprise segments, where Alibaba Cloud, Tencent Cloud, and state-backed entities like China Telecom's eCloud possess massive existing market share, deep integration with local government procurement systems, and aggressive pricing strategies that compress margins and require Huawei to continuously innovate its Pangu AI models and Ascend chip architecture to maintain its position as a top-tier provider. The second component of Huawei's moat is its unparalleled portfolio of standard-essential patents; the company holds over 14% of all 5G essential patents, meaning that any manufacturer building a 5G device, whether it is Apple, Samsung, or Ericsson, must license Huawei's intellectual property, generating hundreds of millions of dollars in annual licensing fees and giving Huawei significant use in cross-licensing negotiations.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Eli Lilly and Company stack up against those of Huawei Technologies Co., Ltd..

Eli Lilly and Company competitive advantage: What makes Lilly's story particularly compelling is not just the scale of its recent success but the specific American geography it inhabits. The competitive landscape in which Eli Lilly operates has been radically reshaped over the past decade, both by the emergence of the GLP-1 drug class as a genuine blockbuster category and by the parallel evolution of oncology and immunology into scientifically sophisticated, targeted medicine domains where first-mover advantages and data depth matter enormously. Verzenio's revenue trajectory suggests it may eventually become the category leader despite entering the market after Ibrance, reflecting the value of superior clinical data over first-mover advantage in targeted oncology. The injectable nature of current tirzepatide formulations represents a patient acceptance barrier that, if removed through an effective oral alternative, would dramatically expand the addressable market. Eli Lilly's competitive advantages are rooted in four interconnected sources that, in combination, create a defensible position in the global pharmaceutical industry that goes beyond any single product success. This domain expertise is not merely historical; it manifests today in Lilly's pipeline of next-generation cardiometabolic molecules including orforglipron (an oral GLP-1 receptor agonist that could eliminate the injection barrier for millions of patients), retatrutide (a triple receptor agonist showing extraordinary weight loss results in Phase 2 trials — an average of 24.2 percent body weight reduction over 48 weeks), and other compounds targeting the intersection of metabolic disease, cardiovascular risk, and kidney function. Trust built through reliable insulin supply over a century translates into prescriber confidence in Lilly's newer products, creating a commercial starting advantage that newer entrants cannot replicate quickly. Fourth, Lilly's manufacturing infrastructure, while currently capacity-constrained, represents a long-term competitive moat. The technical complexity of sterile injectable biologics manufacturing creates meaningful barriers to generic and biosimilar entry, and the company's investments in dedicated tirzepatide manufacturing capacity will eventually provide scale advantages over potential competitors who face the same steep learning curves and capital requirements. By October 1923, Lilly was producing insulin on a commercial scale sufficient to supply diabetic patients across North America, and the company had developed an extract with substantially higher potency and reliability than earlier preparations.

Huawei Technologies Co., Ltd. competitive advantage: The strategic focus for the next three to five years is to increase the revenue contribution of the Cloud and Digital Power segments, scale the HarmonyOS ecosystem to achieve a critical mass of third-party developers, and continue the arduous process of domesticating the semiconductor supply chain to achieve true self-sufficiency in advanced logic and memory production. The business model of Huawei is a masterclass in vertical integration, massive capital allocation, and strategic patience, creating a sustainable, technologically sovereign ecosystem that generates significant revenue without relying on Western intellectual property or manufacturing capabilities. While Huawei successfully engineered the 7-nanometer Kirin 9000s using SMIC's deprecated DUV multi-patterning techniques, this process is inherently less efficient, more expensive, and yields significantly fewer chips per wafer than TSMC's EUV-based 5nm and 3nm nodes, creating a structural cost disadvantage and a persistent yield challenge that limits the volume of premium smartphones Huawei can produce and compresses the gross margins of its consumer electronics division. The vertical integration operates on multiple levels: Huawei designs its own processors through HiSilicon, develops its own operating systems through HarmonyOS and openEuler, manufactures its own production equipment through Nova, builds its own enterprise resource planning systems, and deploys its own network infrastructure, creating a closed-loop ecosystem where every component is optimized for the others, resulting in performance and efficiency gains that are impossible for companies relying on third-party silicon and software to achieve. The technical foundation of this moat is built on a highly optimized, massive R&D engine that employs over 114,000 engineers, representing 55% of the company's total workforce, who are tasked with solving the physics and materials science limitations imposed by the lack of access to leading-edge Western semiconductor manufacturing equipment. This technical superiority, combined with the patent portfolio and the vertical integration, creates a cohesive ecosystem that is exceptionally difficult for competitors to disrupt, as any attempt to replicate the platform must not only match its technical performance but also overcome the massive capital barriers and the decade-long head start in fundamental research. The ongoing evolution of Huawei's competitive advantage will be driven by its ability to scale its domestic semiconductor manufacturing capabilities, expand the HarmonyOS ecosystem to achieve a critical mass of third-party developers, and maintain its leadership in 5G-Advanced and 6G research, all while navigating the complex geopolitical environment surrounding international trade. The second initiative is to scale the Digital Power segment, with a target to capture 30% of the global smart photovoltaic inverter market and 25% of the data center liquid-cooling market by 2027. The third initiative is to achieve critical mass for the HarmonyOS NEXT ecosystem outside of China, with a target to onboard 500,000 native applications and reach 200 million active devices in international markets by 2026. Huawei Technologies Co. Ltd.'s strategic bet for the next three to five years is centered on three primary pillars: achieving total semiconductor supply chain self-reliance, scaling the HarmonyOS ecosystem to become the third major global mobile operating system, and establishing dominance in the intersection of artificial intelligence, automotive intelligence, and digital power infrastructure.

Future prospects matter as much as current results. The growth strategies below explain how Eli Lilly and Company and Huawei Technologies Co., Ltd. each plan to expand from here.

Eli Lilly and Company growth strategy: That insulin partnership with the University of Toronto did not merely save lives; it established Lilly's identity as a science-first organization willing to pursue difficult biological problems across decades rather than quarters. Yet the company continued investing heavily in its research and development infrastructure, spending consistently between 20 and 25 percent of revenues on R&D even in lean years. Retevmo (selpercatinib), a RET kinase inhibitor for RET-altered cancers including certain lung and thyroid malignancies, and Jaypirca (pirtobrutinib), a BTK inhibitor for mantle cell lymphoma and chronic lymphocytic leukemia, represent Lilly's next-generation oncology assets with significant growth trajectories. Europe and Japan represent the next largest markets, with significant growth in emerging markets including China, where Lilly has maintained commercial operations for decades. This investment includes new sterile injectable fill-finish capacity and active pharmaceutical ingredient manufacturing to eliminate supply constraints that limited Zepbound and Mounjaro availability through much of 2023 and into 2024. The Indianapolis-based pharmaceutical company, which has survived Prohibition, the Great Depression, two World Wars, the AIDS crisis, multiple patent cliffs, and a decade of Alzheimer's drug failures, has in the early 2020s assembled what many analysts characterize as the most compelling pharmaceutical growth story of the current era. Ricks prioritized pipeline discipline over diversification, investing deeply in a small number of therapeutic areas where Lilly had genuine scientific depth rather than spreading resources thinly across many programs with mediocre differentiation. The company now invests more in R&D in absolute dollar terms than it generated in total revenues just fifteen years ago, illustrating both how dramatically the company has grown and how aggressively it is reinvesting to sustain that growth trajectory. For investors, healthcare professionals, policymakers, and patients, Lilly's evolution represents a case study in what pharmaceutical companies can achieve when long-term scientific commitment meets the right commercial moment. Lilly's competitive positioning in immunology is solid but not dominant, and the company's strategic priority is increasingly to defend existing Taltz revenues while investing in next-generation immunology candidates that could create new market leadership positions. This rate of growth is nearly unprecedented for a company of Lilly's scale in any industry, and it reflects almost entirely the commercial launch of tirzepatide across its Mounjaro and Zepbound indications. While Lilly's multi-billion-dollar manufacturing investment program is expected to alleviate these constraints by 2026 and 2027, the ramp-up period presents real financial and competitive risk, particularly as rival GLP-1 products from Novo Nordisk and potential new entrants compete for the same prescriber base and pharmacy shelf space. The irony is, Second, Lilly's brand equity among endocrinologists, cardiologists, and primary care physicians reflects decades of relationship-building through clinical education, medical affairs programs, and drug performance in real-world settings. Eli Lilly's growth strategy, as articulated through company investor presentations, earnings calls, and strategic communications under CEO David Ricks, rests on three interconnected pillars: maximizing the commercial potential of approved assets through indication expansion and market access improvement; sustaining pipeline productivity through disciplined internal R&D and targeted external business development; and building the manufacturing infrastructure necessary to support global demand at scale. The indication expansion strategy for tirzepatide is already well advanced. External business development has accelerated meaningfully under Ricks, reflecting a strategic recognition that internal R&D, while productive, cannot alone sustain the pipeline density required to replace revenue from products facing eventual patent expiry. Manufacturing investment represents the operational backbone of the growth strategy, with over $23 billion committed through 2027 to building capacity that will eliminate the supply constraints that have limited tirzepatide access and revenue since commercial launch. The trajectory of Eli Lilly over the next five to ten years is unusually legible by pharmaceutical industry standards, in large part because the company's near-term growth drivers are already approved and scaling and its longer-term pipeline candidates include multiple assets with multi-billion-dollar peak sales potential that have progressed to late-stage clinical development. Among the estimated 100 million Americans with obesity, fewer than 5 percent were receiving any pharmacological treatment as of 2024, suggesting an addressable population that could sustain revenue growth for many years even without new indications. New tirzepatide label expansions under investigation include heart failure with preserved ejection fraction (a trial already demonstrating positive results), sleep apnea, fatty liver disease (NASH/MASH), chronic kidney disease, and potentially cancer risk reduction. In Alzheimer's disease, donanemab (Kisunla) faces the challenge of building commercial infrastructure around a complex treatment model — patients require amyloid confirmation testing, infusion center visits, and MRI monitoring — but the underlying unmet medical need remains enormous, and Lilly is investing in diagnostic partnerships and infusion center networks to remove access barriers. The city was growing rapidly, positioned at the intersection of multiple rail lines that would increasingly define American commerce in the post-war era, and Lilly recognized both a business opportunity and a professional calling. He invested in analytical equipment to test raw materials before they entered production, a practice so unusual in the trade that it became a marketing point — Lilly medicines carried certificates of analysis years before regulatory bodies existed to require such documentation. This commitment to scientific integrity was not merely altruistic; it was a business strategy rooted in the belief that healthcare professionals, if given a choice, would prefer reliably effective medicines over cheaper alternatives that varied wildly in potency and purity. The company grew steadily through the late nineteenth century, expanding its product line from elixirs and tonics to a broader range of pharmaceuticals, moving into gelatin-coated capsules (a technology that significantly improved patient acceptance of medications) in the 1890s, and building a growing export business in Central and South America. The lesson of insulin — that patient, rigorous scientific investment in understanding complex biological mechanisms could produce far-reaching therapeutic outcomes — informed Lilly's research philosophy throughout the twentieth century and provides direct intellectual lineage to the GLP-1 and incretin research that would eventually produce tirzepatide seven decades later.

Huawei Technologies Co., Ltd. growth strategy: The financial data, the technical specifications, and the strategic decisions that define Huawei's operations provide a comprehensive blueprint for understanding the intersection of corporate strategy, national security, and technological sovereignty in the twenty-first century. The journey from the distribution of analog switches to the mass production of 7-nanometer AI processors is a demonstration of the power of strategic patience, massive capital allocation, and the immense value of building complete technological stacks in an era of geopolitical fragmentation. The platform's current trajectory points toward continued growth and innovation, driven by a deep understanding of its core markets and a commitment to providing the most advanced communication and computing infrastructure in the world. The technical specifications, the financial metrics, and the strategic decisions that have shaped Huawei's evolution provide a comprehensive blueprint for how to build a dominant, vertically integrated technology conglomerate in the twenty-first century, a blueprint that will be studied, emulated, and contested by governments and corporations across the globe. The company's success is a direct result of its consistent focus on core technology research, its refusal to compromise on long-term strategic goals for short-term financial gain, and its relentless drive to enable its engineers to solve the most complex problems in physics and materials science. The company's current position as the dominant force in global telecommunications infrastructure is a direct result of the strategic decisions made over the past three decades, when Ren Zhengfei prioritized massive R&D investment and rural market penetration over short-term profitability, a strategy that is now being realized by the 207,000 employees who rely on Huawei's technological leadership every single day to build the infrastructure of the future. Despite being placed on the U.S. Entity List in May 2019, Huawei successfully engineered a complete domestic supply chain substitution, launching the HarmonyOS operating system to over 900 million active devices. Huawei's ability to compete against these giants is predicated on its superior product execution, its massive R&D investment, its vertical integration, and its unique employee-ownership structure, which creates a level of operational efficiency and long-term strategic focus that is exceptionally difficult for larger, more bureaucratic organizations or public companies focused on quarterly earnings to replicate. Huawei's current position as the dominant force in global telecommunications infrastructure and a resurgent force in consumer electronics is a direct result of its consistent focus on core technology research, its refusal to compromise on long-term strategic goals for short-term financial gain, and its relentless drive to enable its engineers to solve the most complex problems in physics and materials science. However, the FY2024 results demonstrate that the company has successfully stabilized its revenue base and returned to high-single-digit growth, driven by the massive expansion of its Digital Power segment, which grew by over 40% year-over-year, and the recovery of its Consumer Business, which grew by over 30% following the launch of the Kirin-powered Mate 60 series. This massive R&D expenditure, while compressing short-term operating margins, is the fundamental engine of Huawei's long-term financial survival and growth, ensuring that its proprietary technology stack remains competitive despite the lack of access to leading-edge Western semiconductor manufacturing equipment. The company's balance sheet remains exceptionally strong, with over $40 billion in cash and cash equivalents, providing it with significant financial flexibility to continue investing in growth initiatives, manage the complex regulatory environment, and weather any macroeconomic headwinds without the need for external capital. The ongoing evolution of Huawei's financial strategy will be driven by a deep understanding of its core markets and a commitment to providing the most advanced communication and computing infrastructure in the world. The ongoing challenge for Huawei is to navigate these complex technical, geopolitical, and competitive headwinds while maintaining the strict R&D investment levels required to stay among the leaders of 5G-Advanced, 6G, and AI research, a balancing act that requires flawless execution and an consistent commitment to long-term strategic goals over short-term financial improvement. The company's strategic focus on the creator economy and the App Directory represents its primary mechanism for increasing revenue per user without compromising its privacy commitments, a strategy that aligns the company's financial incentives with the success of its community leaders and developers. The irony is, the ongoing evolution of Huawei's product roadmap, its financial strategy, and its regulatory compliance efforts will be closely monitored by investors, technologists, and policymakers alike, as the company's decisions will have a profound impact on the future of digital communication and the broader technology sector. The journey from the failure of Fates Forever to the dominance of Discord is a demonstration of the power of strategic agility and the immense value of building infrastructure that enable human connection, a value that has proven to be far more enduring and lucrative than any single video game could ever achieve. The platform's current trajectory points toward continued growth and innovation, driven by a deep understanding of its user base and a commitment to providing the best possible communication experience in an increasingly fragmented digital world. The story of Huawei is still being written, but its foundational chapters have already secured its place as one of the most important and influential technology companies of the modern era, a platform that has fundamentally changed how we interact, collaborate, and build communities in the digital age. The technical specifications, the financial metrics, and the strategic decisions that have shaped Huawei's evolution provide a comprehensive blueprint for how to build a dominant, user-centric technology platform in the twenty-first century, a blueprint that will be studied and emulated by entrepreneurs and executives across the globe. The company's success is a direct result of its consistent focus on the core user experience, its refusal to compromise on privacy and performance, and its relentless drive to enable its community leaders to build and monetize their own digital spaces. The story of Huawei is a story of innovation, resilience, and the far-reaching power of digital communication, a story that continues to unfold as the platform expands its reach and deepens its impact on the way we connect with one another in the digital world. The company's current position as the dominant force in real-time communication is a direct result of the strategic decisions made in the spring of 2015, when Jason Citron looked at the analytics for a failing mobile game and saw the future of digital communication, a future that is now being realized by the 150 million monthly active users who rely on Huawei every single day to talk, hang out, and build communities. This patent dominance is the result of a relentless, twenty-year investment in fundamental research, a strategy that has positioned Huawei not just as a manufacturer, but as a foundational architect of the global telecommunications standards that underpin the modern digital economy. The strategic decision to remain private allows Huawei to maintain complete control over its product roadmap and R&D investments, insulating the company from the quarterly earnings pressures that force public technology companies to prioritize short-term financial metrics over long-term technological sovereignty. Huawei Technologies Co. Ltd.'s growth strategy is centered on three specific, named initiatives with clear targets: scaling the Harmony Intelligent Mobility Alliance, expanding the Digital Power segment's global market share, and achieving critical mass for the HarmonyOS NEXT network outside of China. The first initiative is to transform the automotive intelligence business into a major revenue driver by expanding the Harmony Intelligent Mobility Alliance to include at least five major automakers by 2026, with a target to integrate its smart cockpit and autonomous driving solutions into over one million vehicles annually. This requires continuous innovation in power electronics, integrating AI for maximum energy yield and cooling efficiency, and expanding its sales and service network in Europe, the Middle East, and Latin America to capitalize on the global energy transition and the massive build-out of AI data centers. To support these initiatives, Huawei is investing heavily in its technical infrastructure, expanding its global network of research centers, and developing new machine learning models to improve the efficiency of its AI and digital power products. The company is also expanding its engineering headcount, focusing on hiring top talent in artificial intelligence, semiconductor physics, and power electronics to drive the development of new features and improve the overall product performance. The ongoing evolution of Huawei's growth strategy will be driven by a deep understanding of its core markets and a commitment to providing the most advanced communication and computing infrastructure in the world. The first initiative is to completely domestic the semiconductor manufacturing process, moving beyond the current 7-nanometer DUV multi-patterning techniques to achieve viable 5-nanometer and eventually 3-nanometer production using domestic equipment and advanced packaging technologies like chiplets, a monumental engineering challenge that requires the coordination of hundreds of domestic suppliers and billions of dollars in continuous R&D investment. This strategy is not merely about catching up to TSMC; it is about creating a completely independent, sanctions-proof technology stack that ensures Huawei's access to advanced compute for its AI and 5G-Advanced products, regardless of the geopolitical environment. The second strategic focus is the global expansion of HarmonyOS; while the operating system has achieved massive adoption in China with over 900 million devices, the company is aggressively targeting emerging markets in Southeast Asia, the Middle East, and Latin America, where the geopolitical stigma associated with Huawei is less pronounced and where the demand for a non-Android, non-iOS alternative that offers superior privacy and integration is growing. The company's Harmony Intelligent Mobility Alliance is expanding rapidly, partnering with multiple domestic automakers to produce smart vehicles that are essentially data centers on wheels, generating high-margin software licensing revenue and creating a massive new data stream for its AI models. The lessons learned from these early struggles, including the importance of rural market penetration, the value of employee ownership, and the necessity of massive R&D investment, continue to guide the company's strategic direction and its investment priorities, ensuring that Huawei remains the definitive digital infrastructure provider for the developing world.

A closer look at the financial trajectory of Eli Lilly and Company and Huawei Technologies Co., Ltd. rounds out the comparison.

Eli Lilly and Company: $9.3 billion spent on research and development in fiscal year 2024 — a number that exceeds Lilly's entire revenue base in 2009. That reinvestment rate, sustained over years, is the financial explanation for tirzepatide's commercial performance. Drugs of this clinical quality don't emerge from modest R&D budgets. Net income reached $10.59 billion in FY2025 on $65.2B in revenue, a 23.5% net margin that reflects the pricing power of a drug that genuinely outperforms its competition. The revenue trajectory has been steep: $28.3 billion in 2021, $28.5 billion in 2022, $34.1 billion in 2023, $65.2B in FY2025. Each year's jump is larger than the last, driven by tirzepatide's expansion across indications and geographies. The supply shortage controversy in 2023 had a real financial component. Manufacturing capacity for GLP-1 drugs requires specialized equipment and long lead times. Lilly has committed billions in capital expenditure to expand manufacturing — but the gap between demand and supply means some prescription revenue is being left on the table during a period when competitive dynamics are most favorable. The Loxo Oncology acquisition in 2019 cost approximately $8 billion. The oncology pipeline it delivered — including selpercatinib and other targeted therapies — now contributes revenue that diversifies Lilly's earnings away from the GLP-1 concentration risk. Market capitalization of $700 billion prices in continued GLP-1 dominance and successful Phase 3 outcomes for retatrutide. Either of those assumptions failing would reprice the stock significantly.

Huawei Technologies Co., Ltd.: $118.5 billion in FY2024 revenue against $94.2 billion in 2022 represents 26% growth over two years while operating under comprehensive U.S. Sanctions. Net income of $8.6 billion implies a 7.3% net margin — modest relative to revenue, but reflecting the massive R&D reinvestment that consumed $27.7 billion of the top line. The Digital Power segment growing over 40% year-over-year to approximately $21 billion in FY2024 is the clearest signal of where the company is directing growth capital. Smart photovoltaic inverters and data center liquid cooling are infrastructure components for China's energy transition — a market that is growing rapidly and where Western sanctions have no direct impact. The private valuation of approximately $120 billion, maintained through secondary employee share transactions rather than public markets, means there is no external shareholder pressure to maximize short-term returns. The employee-ownership structure and the trade union committee governance allow the company to sustain the 23.4% R&D spending rate even when it compresses near-term profitability. The exclusion from 5G core networks in European Union countries, the United Kingdom, Australia, and the Five Eyes alliance has permanently reduced the total addressable market for Huawei's telecommunications equipment business. Quantifying the revenue foregone is difficult — but the strategic response of accelerating Digital Power and cloud infrastructure in domestic and non-Western markets suggests management has treated the Western exclusion as fixed rather than reversible.